

University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
March 17, 2026

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chatterjee, Bandana; Chen, Chun-Liang; Dell, Shelbie; Ginsburg, Brett; Gould, Georgianna; Kautz, Tiffany; Martinez-Sobrido, Luis; Prewit, Egle; Salamango, Daniel; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Barlett, Emily.

Absent members: Cerecero, Jennifer; Chen, Ching-Kang Jason; Gauduin, Marie Claire; Mishra, Bibhuti; Paukert, Martin; Shiio, Yuzuru.

1. Panel Chair Announcement

The meeting was called to order at 11:00 a.m. by the IBC Chair, Dr. Yan Xiang.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the February 17, 2026, IBC meeting.

Approved (17 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of FY2026 approved protocols will be sent out for review in April 2026.

5. Old Business –

6. Educational Items – None

7. Occupational Medicine- As of March 1, 2026, there were five cases of needlesticks, all of which were by UT staff members. There were five cases of bloodborne exposure: two were by students, and three were by UT staff members. There were six cases of Occupational injuries, three were by students and three by UT

staff members. There was a chemical exposure by a UT staff member.

8. Other – None

9. Review of EHS Assistant-

Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on April 14, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000021629

Principal Investigator: Hiroi, Noboru; Pharmacology

Title: N/A

Review Type: Full Committee Review

Form Type: Amendment

Approved (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with Human Neural stem cells at BSL-2 containment. Work with AAV vectors (AAV Dger8 shRNA, AAV Zfp516 shRNA, AAV Mbp shRNA) at BSL-1 containment. Work with new knock-out mouse strains (Zfp516, Fmr1) and transgenic mouse strain (Mesp2-Cre) at ABSL-1 containment.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

12. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000021420

Principal Investigator: Li, Hong-Yu; Pharmacology

Title: N/A

Review Type: Full Committee Review

Form Type: Amendment

Approved (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with (replication-incompetent) defective Lentivirus, human cell lines (HCC1806, CaCo2, HEK293), and vectors (pcDNA, pCMV-VSV-G, pLenti-CMV-MCS-GFP-SV-puro) at BSL-2 containment. Work with E. coli DH5 alpha at BSL-1 containment.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:


Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Adjourn: The meeting adjourned at 11:18 A.M.



Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam